Abeona Therapeutics (ABEO) Receivables (2010 - 2026)

Abeona Therapeutics' Receivables history runs 16 years deep, the most recent figure standing at $6.6 million for Q1 2026.

• In Q1 2026, Receivables changed N/A year-over-year to $6.6 million; the TTM figure through Mar 2026 stood at $6.6 million (changed N/A YoY), while the FY2025 annual figure was $6.6 million, changed N/A from the prior year.
• Receivables was $6.6 million for Q1 2026 at Abeona Therapeutics, down from $6.6 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $27.3 million in Q3 2022 to a low of $3.4 million in Q2 2022.
• Historically, Receivables has averaged $9.9 million across 4 years, with a median of $6.6 million in 2026.
• Biggest YoY gain for Receivables was 66.22% in 2023; the steepest drop was 66.22% in 2023.
• A 4-year view of Receivables shows it stood at $27.3 million in 2022, then plunged by 79.52% to $5.6 million in 2023, then rose by 18.7% to $6.6 million in 2025, then declined by 0.71% to $6.6 million in 2026.
• The last three Receivables figures came in at $6.6 million (Q1 2026), $6.6 million (Q4 2025), and $5.6 million (Q2 2023), per Business Quant data.